Related Experiment Video
Updated: Sep 16, 2025
09:00
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
849
Proteomics in pancreatic cancer
Fei Cai1, Yufan Gu1, Yingying Ling1
1Department of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, 610041, China.
Biomarker Research
|July 6, 2025
Summary
Pancreatic cancer (PC) detection remains challenging due to late diagnosis. This review explores mass spectrometry-based proteomics for discovering new PC biomarkers and therapeutic targets, aiming for earlier detection and improved outcomes.
Area of Science:
- Oncology
- Proteomics
- Biomarker Discovery
Background:
- Pancreatic cancer (PC) is highly aggressive with poor prognosis, often diagnosed at advanced stages.
- Current diagnostic and prognostic tools for PC are insufficient, necessitating novel approaches.
- Early detection is crucial for effective pancreatic cancer treatment strategies.
Purpose of the Study:
- To systematically review recent advancements in clinical proteomic techniques for pancreatic cancer.
- To highlight significant biomarker discoveries and signaling pathways in PC.
- To provide insights into PC molecular mechanisms for new diagnostic and therapeutic targets.
Main Methods:
- Systematic review of mass spectrometry (MS)-based proteomics applications in pancreatic cancer.
- Integration of findings on biomarker discoveries and signal transduction networks.
- Analysis of recent advancements in clinical proteomic techniques.
Main Results:
- Mass spectrometry-based proteomics offers extensive applications in disease diagnostics and drug target screening.
- Significant biomarker discoveries and signal transduction networks associated with PC have been identified.
- Recent advancements provide novel insights into PC development and progression.
Conclusions:
- There is an urgent need for innovative approaches to detect pancreatic abnormalities early.
- Proteomics holds promise for identifying new diagnostic biomarkers and therapeutic targets for pancreatic cancer.
- Understanding molecular mechanisms through proteomics can improve PC management.
